RedHill Biopharma annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
RedHill Biopharma Revenue Growth & History (RDHL)
RedHill Biopharma reported $286,000 in revenue for fiscal 2025, a decrease of 96.44% from the previous fiscal year.
View full RedHill Biopharma company overviewRedHill Biopharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $286,000 | −$7.8M | −96.44% |
| 2024 | 2024-12-31 | $8.0M | $1.5M | +23.17% |
| 2023 | 2023-12-31 | $6.5M | −$55.3M | −89.43% |
| 2022 | 2022-12-31 | $61.8M | −$24.0M | −27.94% |
| 2021 | 2021-12-31 | $85.8M | $21.4M | +33.25% |
| 2020 | 2020-12-31 | $64.4M | $58.1M | +923.03% |
| 2019 | 2019-12-31 | $6.3M | −$2.1M | −24.75% |
| 2018 | 2018-12-31 | $8.4M | $4.4M | +108.63% |
| 2017 | 2017-12-31 | $4.0M | $3.9M | +3867.33% |
| 2016 | 2016-12-31 | $101,000 | $98,000 | +3266.67% |
| 2015 | 2015-12-31 | $3,000 | — | — |
RedHill Biopharma quarterly revenue
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2022 | 2022-06-30 | $18.3M | −$3.2M | −14.68% |
| Q2 2021 | 2021-06-30 | $21.5M | $603,000 | +2.89% |
| Q2 2020 | 2020-06-30 | $20.9M | $19.3M | +1237.11% |
| Q2 2019 | 2019-06-30 | $1.6M | −$787,000 | −33.49% |
| Q2 2018 | 2018-06-30 | $2.4M | $1.9M | +386.54% |
| Q2 2017 | 2017-06-30 | $483,000 | — | — |
RedHill Biopharma revenue growth trends
Over the last five reported fiscal years, revenue declined from $64.4M to $286,000, a compound annual decline of 66.15%. RedHill Biopharma's latest reported quarter, Q2 2022, generated $18.3M in revenue, a decrease of 14.68% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review RedHill Biopharma source filings ↗Community posts
RedHill reports wider first-half loss amid commercial-portfolio transition
RedHill Biopharma ($RDHL) reported a first-half net loss of $6.1 million, compared with $4.1 million a year earlier, and no revenue from continuing operations. Operating cash use was $4.6 million, while the half-year cash balance stood at $ ...
